1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Illinois >
  6. LeMaitre Vascular Acquires Restore Flow Allograft

M&A Deal Summary

LeMaitre Vascular Acquires Restore Flow Allograft

On November 10, 2016, LeMaitre Vascular acquired life science company Restore Flow Allograft for 14M USD

Acquisition Highlights
  • This is LeMaitre Vascular’s 3rd transaction in the Life Science sector.
  • This is LeMaitre Vascular’s 4th largest (disclosed) transaction.
  • This is LeMaitre Vascular’s 5th transaction in the United States.
  • This is LeMaitre Vascular’s 1st transaction in Illinois.

M&A Deal Summary
Date 2016-11-10
Target Restore Flow Allograft
Sector Life Science
Buyer(s) LeMaitre Vascular
Deal Type Add-on Acquisition
Deal Value 14M USD

Target

Restore Flow Allograft

Fox River Grove, Illinois, United States
Restore Flow Allograft LLC is a provider of research for restorative transplantation and preservation of donated allograft tissue for medical treatment.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

LeMaitre Vascular

Burlington, Massachusetts, United States
Category Company
Founded 1983
Sector Medical Products
Employees651
Revenue 220M USD (2024)
DESCRIPTION

LeMaitre Vascular is a provider of devices for the treatment of peripheral vascular disease. LeMaitre Vascular was founded in 1983 and is based in Burlington, Massachusetts.

DEAL STATS #
Overall 6 of 8
Sector: Life Science M&A 3 of 4
Type: Add-on Acquisition M&A Deals 2 of 3
State: Illinois M&A 1 of 1
Country: United States M&A 5 of 6
Year: 2016 M&A 2 of 2
Size (of disclosed) 4 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-03-18 ProCol Vascular Bioprosthesis

United States

ProCol Vascular Bioprosthesis is a natural biological graft derived from a bovine mesenteric vein that provides vascular access for end-stage renal disease ("ESRD") hemodialysis patients. It is intended for the creation of a bridge graft for vascular access subsequent to at least one previously failed prosthetic access graft.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-10-13 Admedus - Biologic Patch Business

Perth, Australia

Admedus Ltd.'s Biologic Patch Business is a provider tissue processing technology to the CardioCel and VascuCel product lines.

Buy $16M
Mergr

Solution for

Product

Company

Legal